Active Ingredient History

NOW
  • Now
Dactinomycin (actinomycin D) was isolated from Streptomyces by Selman Waksman in 1940s. The antibiotic shows anti-cancer activity; it was approved by FDA for the treatment of different cancer conditions among which are Ewing's sarcoma, Wilm's tumor, gestational trophoblastic disease, etc. Dactinomycin exerts its action by binding to DNA (preferably to GC motif) and thus inhibiting transcription.   NCATS

  • SMILES: CC(C)[C@H]1NC(=O)[C@@H](NC(=O)C2=CC=C(C)C3=C2N=C4C(O3)=C(C)C(=O)C(N)=C4C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]7CCCN7C1=O
  • InChIKey: RJURFGZVJUQBHK-IIXSONLDSA-N
  • Mol. Mass: 1255.417
  • ALogP: Missing data
  • ChEMBL Molecule:
More Chemistry
  • Mechanisms of Action: Missing data
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$630.7200 - $936.0200
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

2-amino-n,n'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1h-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-dicarboxamide | actactinomycin a iv | actd | actinomycin | actinomycin 7 | actinomycin c1 | actinomycin d | actinomycin-d | actinomycin iv | c1 | chounghwamycin b | cosmegen | cosmegen lyovac | dactinomicina | dactinomycin | dactinomycin d | dactinomycine | dactinomycinum | dilactone actinomycin d acid | dilactone actinomycindioic d acid | gnf-pf-1977 | gnf-pf-2290 | meractinomycin | oncostatin k

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue